BIOCON

June 30 (Reuters) - Biocon Ltd BION.NS:

• BIOCON - BIOCON BIOLOGICS EXPANDS INSULIN ACCESS IN MALAYSIA

Source text: ID:nNSE3PN7yT

Further company coverage: BION.NS

(([email protected];))

SHANGHAI, June 27 (Reuters) - Indian drugmaker Biocon BION.NS has abandoned plans to market generic versions of Novo Nordisk’s NOVOb.CO hot-selling diabetes and weight-loss drugs in China due to local competition, a senior executive said.

"We decided not to do it in China, not supply or register the product in China, either finished product or the API, because there is ample capacity and players available in China," Amit Kaptain, head of Biocon's commercial active pharmaceutical ingredients (API) business, told Reuters in Shanghai.

Kaptain had said in 2024 that Biocon was aiming to launch its versions of Novo's diabetes and weight-loss drugs Ozempic and Wegovy in the world’s second-biggest economy after clinical trials.

Biocon's diabetes and weight-loss products would have joined at least 15 other generics or biosimilars in development by Chinese drugmakers, Reuters has reported. Biosimilars are versions of a drug that are highly similar to approved medications.

Chinese drugmakers have rushed to develop generics or biosimilars as the patent for semaglutide, a key ingredient in both Ozempic and Wegovy, ends in early 2026 in China.

The number of adults in China who are overweight is projected to reach 540 million in 2030 and those who are obese 150 million, increases of 2.8 and 7.5 times respectively from the year 2000, according to a 2020 study by Chinese public health researchers.

(Reporting by Andrew Silver; Editing by Miyoung Kim and Tom Hogue)

(([email protected]; 65 6870 3026; Reuters Messaging: [email protected]))

June 20 (Reuters) - Biocon Ltd BION.NS:

• RAISES 45 BILLION RUPEES THROUGH QIP

Source text: ID:nBSE1N5x1G

Further company coverage: BION.NS

(([email protected];;))

** Shares of drug maker Biocon BION.NS rise 2.5% to 350.5 rupees apiece

** HSBC reiterates "buy" on BION, saying that a successful QIP (qualified institutional placement, a fundraising tool) should ease debt burden

** On Monday, BION launched a QIP to raise 45 billion rupees to pay off financial obligations

** Easing debt burden to help BION sharpen its focus on biosimilars scale-up, says HSBC

** Remains positive about the turnaround of BION's biosimilars segment and says the execution of upcoming launches crucial for BION

** Trims target price to 390 rupees from 400 rupees to account for the rising shareholder base after the QIP

** HSBC's new target price implies a 10.6% upside for BION

** The average rating of 15 analysts tracking BION is buy; median target price is 395 rupees, data compiled by LSEG shows

** BION shares are down 6.4% in 2025 so far, mirroring the 8.3% fall in pharma index .NIPHARM, exchange data shows

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

June 2 (Reuters) - Biocon Ltd BION.NS:

• BIOCON LTD - RECEIVES APPROVAL FOR LIRAGLUTIDE DRUG IN INDIA

• BIOCON LTD - RECIEVED APPROVAL FOR GENERIC VERSION OF VICTOZA FOR TYPE 2 DIABETES

Further company coverage: BION.NS

(([email protected];))

May 21 (Reuters) - Biocon Ltd BION.NS:

• BIOCON BIOLOGICS AND YOSHINDO EXPAND ACCESS TO USTEKINUMAB BIOSIMILAR IN JAPAN

Source text: [ID:]

Further company coverage: BION.NS

(([email protected];;))

May 8 (Reuters) - Biocon Ltd BION.NS:

• IN FY26, WE EXPECT TO SEE A RECOVERY IN API BUSINESS

• FOCUSED ON STRATEGIC EXPANSION OF DIFFERENTIATED GLP-1 PORTFOLIO INTO NEW MARKETS

Source text: ID:nBSE9XfQ98

Further company coverage: BION.NS

(([email protected];;))

May 5 (Reuters) - Biocon Ltd BION.NS:

• BIOCON BIOLOGICS SECURES STRONG MARKET ACCESS COVERAGE FOR YESINTEK IN THE UNITED STATES

Source text: ID:nBSE8NV3PQ

Further company coverage: BION.NS

(([email protected];;))

April 23 (Reuters) - Indian biopharma firm Biocon BION.NS said on Wednesday it will raise funds worth up to 45 billion rupees ($527.3 million) via issue of securities, which may include debt and selling shares to institutional investors.

($1 = 85.3420 Indian rupees)

(Reporting by Hritam Mukherjee in Bengaluru; Editing by Krishna Chandra Eluri)

(([email protected]; X: @MukherjeeHritam;))

April 15 (Reuters) - Biocon Ltd BION.NS:

• BIOCON LTD - BIOCON BIOLOGICS SECURES U.S. MARKET ENTRY FOR YESAFILI BIOSIMILAR

• BIOCON LTD - YESAFILI TO LAUNCH IN U.S. IN SECOND HALF OF 2026 OR EARLIER

• BIOCON - BIOCON BIOLOGICS, REGENERON EXECUTED SETTLEMENT AGREEMENT TO DISMISS PENDING APPEAL

Source text: ID:nBSEz8sQy

Further company coverage: BION.NS

(([email protected];))

** Shares of biopharma firm Biocon BION.NS climb 3.5% to 320 rupees

** The U.S. FDA approvesco's biosimilar drug, Jobevne, which combats cancer by restricting blood supply to the tumor

** Separately, the U.S. FDA also approvesunit's drug Everolimus, used to treat organ rejection in kidney and liver transplantation

** Biocon is the third-biggest gainer in the Nifty pharma index .NIPHARM, which is up 2.5%, tracking broader markets after the U.S. paused steep reciprocal tariffs

** Stock down 13% so far in 2025 vs a 12.5% drop in the pharma index

(Reporting by Nishit Navin)

(([email protected];))

April 10 (Reuters) - Biocon Ltd BION.NS:

• BIOCON LTD - U.S. FDA APPROVES BIOCON BIOLOGICS'S BEVACIZUMAB BIOSIMILAR, JOBEVNE

Source text: ID:nNSE5l9jrj

Further company coverage: BION.NS

(([email protected];))

Adds analyst comments in paragraphs 11-12, updates share moves throughout

By Manas Mishra and Ananta Agarwal

April 9 (Reuters) - Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and as his country-specific reciprocal tariffs took effect, leading to more pain in global markets.

Pharmaceutical imports were initially exempt from Trump's first set of reciprocal tariffs last week — but his administration has since indicated that levies on the sector, which in the past has been excluded from such actions, are coming.

The U.S. president has said the tariffs will incentivize drug companies to move operations to the United States. However, analysts and companies have raised concerns about the difficulty in setting up manufacturing in the country.

Shares of major U.S. drugmakers Amgen AMGN.O, AbbVie ABBV.N, Pfizer PFE.N, Merck MRK.N and Eli Lilly LLY.N fell between 3% and 6% in premarket trading.

In Europe, a basket of healthcare stocks .SXDP fell 5% to its lowest since October 2022, leading losses among sectoral indexes on the region-wide STOXX 600 .STOXX, which was down 3.3% at 1013 GMT. The index was heading for its biggest one-day drop since March 2020.

Trump had also threatened the duties on Friday after his first set of "reciprocal" tariffs exempted pharma products. Trump has not said when and by how much he plans to raise levies on pharma imports.

"While the details are scant, we are strongly opposed to tariffs on any pharmaceuticals — these will likely do little to shift manufacturing back to the U.S.," said BMO Capital Markets analyst Evan Seigerman.

"Given the complexity of the pharma supply chain, we do not expect the industry to make any major changes. These current tariffs are being pursued under emergency powers, which at worse will last until the end of the current administration and could end sooner with an act of Congress."

Seigerman also pointed to concerns over recent layoffs at the U.S. Food and Drug Administration, saying the worries were now compounded by the "real talk" of pharma tariffs.

ADDITIONAL COSTS, LONG WAIT FOR PRODUCTION

Europe and the U.S. have interconnected supply chains for medicines. The United States depends on medicines partly produced in Europe that bring in hundreds of billions of dollars in revenue.

Bernstein analyst Courtney Breen wrote in a note that her worst-case scenario assumes tariffs could be steep, leading to about $53 billion in additional costs paid for pharmaceutical imports.

If companies did choose to bring new manufacturing to the United States, Breen expects additional spend of $2 billion for each new "green field" site and a five-year runway to production.

EU medical and pharmaceutical product exports to the U.S. totaled about 90 billion euros ($97 billion) in 2023, according to latest Eurostat data.

Shares of AstraZeneca AZN.L, GSK GSK.L, Roche ROG.S, Sanofi SASY.PA and Novartis NOVN.S fell between 5% and 6.5% in Europe. Meanwhile, Indian pharmaceutical stocks .NIPHARM closed nearly 2% lower, dragging down the benchmark Nifty 50 .NSEI by 0.6%.

IPCA Laboratories IPCA.NS, Glenmark Pharma GLEN.NS and Biocon BION.NS were the top losers by percentage on the pharma index in Mumbai, ending the trading session between 4% and 5.5% lower.

India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. The United States accounts for a third of India's overall pharma exports.

(Reporting by Kashish Tandon, Ananta Agarwal and Manas Mishra in Bengaluru and Anna Pruchnicka in Gdansk; Editing by Savio D'Souza, Mrigank Dhaniwala and Shounak Dasgupta)

(([email protected]))

April 4 (Reuters) - Biocon Ltd BION.NS:

• APPROVES ISSUANCE OF COMMERCIAL PAPERS UP TO 6 BILLION RUPEES

Source text: ID:nBSE2jScWY

Further company coverage: BION.NS

(([email protected];))

April 1 (Reuters) - Biocon Ltd BION.NS:

• BIOCON LTD - TO CONSIDER FUND RAISING THROUGH COMMERCIAL PAPERS ON APRIL 4, 2025

Source text: ID:nBSE5rghRV

Further company coverage: BION.NS

(([email protected];))

March 24 (Reuters) - Biocon Ltd BION.NS:

• UNIT GETS APPROVAL FROM THE U.S. FDA FOR ITS ANDA NOREPINEPHRINE BITARTRATE INJECTION

Source text: [ID:]

Further company coverage: BION.NS

(([email protected];;))

March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.

India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:

NOVO NORDISK

The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.

Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.

SUN PHARMA

Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.

The drugmaker said earlier this month it expects to launch the drug in the next four to five years.

BIOCON

Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.

ZYDUS LIFESCIENCES

India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.

CIPLA

Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.

Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.

DR. REDDY'S

India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.

LUPIN

India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.

NATCO, MANKIND PHARMA, AUROBINDO PHARMA

Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.

Reuters was not able to independently verify the reports.

(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)

(([email protected];))

Corrects deal value in headline, paragraph 1 to $36.5 million, from $50 million

March 10 (Reuters) - India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent Manufacturing Operations Baltimore, a unit of Emergent BioSolutions EBS.N, for $36.5 million.

The contract research firm's acquisition of the facility aligns with broader industry efforts to reduce dependence on China by expanding capabilities in other regions.

The facility, which the contract research firm said is strategically located near key biotech hubs in the Northeast U.S., is expected to be operational for client projects from the second half of 2025.

This acquisition, expected to close in March 2025, will boost Syngene's total single-use bioreactor capacity to 50,000 liters from 20,000 liters, enhancing its capabilities in large molecule discovery, development and manufacturing services.

"In the short term, we expect minor dilution of operating margins as a result of costs to be incurred in this facility," Deepak Jain, Syngene International's chief financial officer, said.

India's contract research development and manufacturing organisation sector has the potential to grow seven-fold to $22 billion-$25 billion by 2035, according to a report by Boston Consulting Group.

(Reporting by Yagnoseni Das in Bengaluru; Editing by Vijay Kishore)

(([email protected];))

March 7 (Reuters) - Biocon Ltd BION.NS:

• BIOCON BIOLOGICS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 STUDY OF YESINTEK™ BIOSIMILAR TO USTEKINUMAB FOR CHRONIC PLAQUE PSORIASIS

• BIOCON LTD - YESINTEK DEMONSTRATES EQUIVALENT EFFICACY AND SAFETY TO STELARA

Source text: ID:nPn6k3Q9ta

Further company coverage: BION.NS

([email protected])

March 6 (Reuters) - Biocon Ltd BION.NS:

• BIOCON BIOLOGICS AND CIVICA, INC. COLLABORATE TO EXPAND INSULIN ASPART ACCESS IN US

Source text: ID:nBSE484mXh

Further company coverage: BION.NS

(([email protected];;))

March 4 (Reuters) - Biocon Ltd BION.NS:

• BIOCON - SUBSIDIARY RECEIVED FINAL APPROVALS FOR ITS ANDAS FROM U.S. FDA

• BIOCON - APPROVALS FOR LENALIDOMIDE CAPSULES, DASATINIB TABLETS

• BIOCON - BIOCON PHARM RECEIVED TENTATIVE APPROVAL FOR RIVAROXABAN TABLETS

Source text: ID:nBSE1Z652g

Further company coverage: BION.NS

(([email protected];;))

Feb 28 (Reuters) - Biocon Ltd BION.NS:

• LAUNCHES GLP-1 PEPTIDE LIRAGLUTIDE IN THE U.K.

Source text: ID:nBSE6zTWvJ

Further company coverage: BION.NS

(([email protected];;))

** Shares of Biocon BION.NS rise nearly 2%, set to snap 7-day losing run

** Biopharma co says unit launches YESINTEK, a biosimilar to Stelara, in the U.S. to treat chronic autoimmune diseases

** Analysts avg rating is 'buy'; median PT is 400 rupees vs current price of 327 rupees -LSEG data

** BION shed nearly 11% in 7-day losing streak and is down about 12% YTD

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

Feb 24 (Reuters) - Biocon Ltd BION.NS:

• BIOCON LTD - BIOLOGICS LAUNCHES YESINTEK BIOSIMILAR IN THE U.S.

Source text: ID:nBSEbJSdHv

Further company coverage: BION.NS

(([email protected];;))

Feb 18 (Reuters) - Biocon Ltd BION.NS:

• EUROPEAN COMMISSION APPROVES BIOCON BIOLOGICS’ USTEKINUMAB BIOSIMILAR

Further company coverage: BION.NS

(([email protected];;))

The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Workspace/Eikon users can register at DAY/US. Thomson One users can register at RT/DAY/US. All times in ET/GMT

The U.S. Labor Department's closely watched employment report is expected to show that in January, nonfarm payrolls increased by 170,000 jobs after recording a rise of 256,000 jobs in December. Private payrolls probably rose by 141,000 jobs, compared with 223,000 jobs in the prior month. Meanwhile, the unemployment rate is likely to come in at 4.1% in January, similar to prior month's reading. Additionally, average hourly earnings likely inched up 0.3% in January, while, on annual basis, average hourly earnings is forecast to have risen 3.8% after posting a 3.9% growth in December. Also, the Commerce Department's Census Bureau is expected to report that wholesale inventories fell 0.5% in December, matching previous month’s figure. Separately, the preliminary reading of the University of Michigan's consumer sentiment index for February is likely to remain unchanged at 71.1.

Federal Reserve Board Governor Michelle Bowman is expected to speak on bank regulation before the 2025 Wisconsin Bankers Association Bank Executives Conference in Milwaukee. (0925/1425) Meanwhile, Fed Board Governor Adriana Kugler is due to speak on "Entrepreneurship and Aggregate Productivity" before the 2025 Miami Economic Forum in Miami. (1200/1700)

Cboe Global Markets is set to release its fourth-quarter results. Analysts expect a rise in profit.

Kimco Realty is expected to post a rise in fourth-quarter revenue, helped by strong demand for rental spaces. Investors will look out for 2025 forecast and comments on competition in commercial space leasing.

Sam Altman, co-founder and CEO of OpenAI, is slated to participate in a panel at the Technical University Berlin on artificial intelligence.

Belgium-based cement producer Titan America is expected to list its shares on the New York Stock Exchange, seeking a valuation of up to $3.32 billion.

Cable providers Comcast and Charter Communications are set to defend at a trial against allegations that their software infringes patents owned by software developer Touchstream related to streaming videos from one screen to another.

Biocon and Viatris' Mylan is set to ask a U.S. appeals court to overturn a ruling that their proposed biosimilars of Regeneron's blockbuster eye-care drug Eylea would infringe Regeneron's patents.

Statistics Canada is expected to show that the Canadian economy likely added 25,000 jobs in January, after recording a rise of 90,000 jobs in December. Meanwhile, the unemployment rate probably inched up to 6.8% in January from 6.7% in December.

In Latin America, Brazil's inflation, as measured by the IGP-DI price index, is expected to have increased 0.08% in January, following a 0.87% rise in the previous month. Additionally, the country’s trade ministry is due to report that trade surplus likely shrank to $3.015 billion in January, from $4.803 billion in the prior month. Meanwhile, Mexico’s consumer prices for January is expected to rise 0.31% and 3.61% on annual basis. Core consumer price index is likely to have increased 0.45% last month. Meanwhile, the country's January PPI figures are also due for release. Chile’s statistics agency, INE, is expected to report that consumer prices rose 0.9% in January. Additionally, the country is likely to post a trade surplus of $2.62 billion for January, up from a surplus of $2.39 billion posted in December.

LIVECHAT-REUTERS GLOBAL MARKETS FORUM

Week in review with Jamie McGeever, Reuters markets columnist, to recap the major themes and events in financial markets and preview the week ahead. (0900/1400) To join the conversation, click here

(Compiled by Lactus Fernandes in Bengaluru; Edited by Sahal Muhammed)

(([email protected];))

Repeats with no change to text or headline

By Rishika Sadam

HYDERABAD, Jan 31 (Reuters) - Indian biopharmaceutical firm Biocon BION.NS is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a top executive told Reuters on Friday.

The company plans to launch five new biosimilars in the U.S. in the new fiscal year, starting in April, and is aspiring for double-digit market share for them, Biocon Biologics CEO Shreehas Tambe told Reuters in an interview.

Biosimilars are similar and relatively affordable versions of high-priced and complex biologics drugs used to treat illnesses such as cancer and autoimmune diseases.

"We needed to be in charge and control of the business (before taking the company public). I think we're pretty much there... We should be looking at the next 12-15 months to this fiscal, which is March 2026 (for listing)," Tambe said.

The company, which has been pushing its IPO plans for the past year, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt before it goes public.

The new U.S. launches, in addition to four existing biosimilars, will focus on therapy areas including diabetes, oncology and immunotherapy.

The company's existing biisimilars have a 20% market share, Tambe said.

The U.S. contributes about 40% in revenue to Biocon Biologics, followed by 35% from Europe where the company plans to launch three new biosimilars in the next 18 months.

The firm hopes to benefit from U.S. President Donald Trump's stand on healthcare affordability, Tambe said.

"..there is a bipartisan view on on bringing affordability to healthcare and I think biosimilars have a big role to play in this," he said.

(Reporting by Rishika Sadam; Editing by Sonia Cheema)

(([email protected];))

By Rishika Sadam

HYDERABAD, Jan 31 (Reuters) - Indian biopharmaceutical firm Biocon BION.NS is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a top executive told Reuters on Friday.

The company plans to launch five new biosimilars in the U.S. in the new fiscal year, starting in April, and is aspiring for double-digit market share for them, Biocon Biologics CEO Shreehas Tambe told Reuters in an interview.

Biosimilars are similar and relatively affordable versions of high-priced and complex biologics drugs used to treat illnesses such as cancer and autoimmune diseases.

"We needed to be in charge and control of the business (before taking the company public). I think we're pretty much there... We should be looking at the next 12-15 months to this fiscal, which is March 2026 (for listing)," Tambe said.

The company, which has been pushing its IPO plans for the past year, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt before it goes public.

The new U.S. launches, in addition to four existing biosimilars, will focus on therapy areas including diabetes, oncology and immunotherapy.

The company's existing biisimilars have a 20% market share, Tambe said.

The U.S. contributes about 40% in revenue to Biocon Biologics, followed by 35% from Europe where the company plans to launch three new biosimilars in the next 18 months.

The firm hopes to benefit from U.S. President Donald Trump's stand on healthcare affordability, Tambe said.

"..there is a bipartisan view on on bringing affordability to healthcare and I think biosimilars have a big role to play in this," he said.

(Reporting by Rishika Sadam; Editing by Sonia Cheema)

(([email protected];))

HYDERABAD, Jan 30 (Reuters) - Indian biopharma company Biocon BION.NS reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which included revenue from its domestic branded formulation business that has since been divested.

The Bengaluru-based company, which counts the U.S. as its key market, reported revenue from operations of 38.2 billion rupees ($441.39 million) for the quarter, compared with 39.54 billion rupees a year earlier.

Revenue from Biocon's biosimilars business, its largest, fell 7.9% to 22.9 billion rupees. Biosimilars are copies of high-priced drugs used to treat illnesses such as rheumatoid arthritis and cancer.

After adjustments, the company's revenue from operations rose 10% on a like-for-like basis, according to Biocon.

Its generics division, however, has been under pressure due to pricing challenges and a planned facility shutdown, the company said in November.

Revenue from the generics unit fell 2.4%, while revenue from its research services business rose 11%.

Biocon, which expects a recovery in its generics business in the next few quarters, is banking on its portfolio of obesity drugs, which have seen skyrocketing demand in global markets.

The company reported a consolidated net profit of 251 million rupees in the third quarter, compared with 6.6 billion rupees a year earlier when it had recorded gains related to dilution of Biocon's stake in its associate company Bicara and the divestment of its domestic formulation business.

The company's quarterly results were also impacted due to tax expenses, Biocon said.

The company increased its equity shareholding in its biologics unit by 1.5% for 5.6 billion rupees and expects the purchase to be completed by next month.

($1 = 86.5450 Indian rupees)

(Reporting by Rishika Sadam in Hyderabad; Editing by Shounak Dasgupta)

(([email protected]))

Jan 29 (Reuters) - Biocon Ltd BION.NS:

• ISSUE OF COMMERCIAL PAPERS OF 5.7 BILLION RUPEES

Source text: ID:nBSE6VMDF8

Further company coverage: BION.NS

(([email protected];;))